Treatment
Dolutegravir clinical trials
We’re tracking 22 recruiting studies that include Dolutegravir, each written for real people, not researchers, below.
Recruiting studies
- NCT07555431RecruitingPhase 2
Dolutegravir alone versus with tenofovir for HTLV-1
This study tests whether adding tenofovir (an antiviral medication) to dolutegravir helps treat HTLV-1 infection better than dolutegravir alone. HTLV-1 is a virus that can cause serious health problems, and researchers want to find the most effective treatment combination.
Salvador, Estado de BahiaAges 18 years+ - NCT05652478RecruitingPhase 2
How HIV prevention drugs affect metabolism in healthy people
This study tests how certain HIV prevention drugs affect the body's metabolism (how it uses energy) in healthy people. It aims to understand side effects before these drugs are used more widely, which could help make future treatments safer.
Bethesda, MarylandAges 18–55 - NCT06747507RecruitingPhase 3
Ndovu study: best HIV treatment for drug resistance
This trial is for people with HIV who are not responding well to the drug dolutegravir (DTG). It tests if switching to a different drug, darunavir/ritonavir (DRV/r), works better than continuing DTG when resistance has developed.
KisumuAges 3 years+ - NCT06203132RecruitingPhase 3
Doravirine vs Dolutegravir for first-time HIV treatment
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
Nova Iguaçu, Rio de JaneiroAges 18 years+ - NCT06967753RecruitingPhase 4
Switching to a two-drug HIV regimen for transgender women
This trial tests if switching to a two-drug combination of dolutegravir and lamivudine is safe and effective for transgender women who already have undetectable HIV levels on a three-drug regimen. It aims to simplify treatment and reduce side effects.
Buenos Aires, Buenos Aires F.D.Ages 18 years+ - NCT04892654RecruitingPhase 3
Doravirine plus dolutegravir switch for people with HIV
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
LondonAges 18 years+ - NCT06281834RecruitingPhase 1
Dolutegravir levels with TB prevention in children
This study tests how dolutegravir (an HIV medicine) works in children when taken with weekly rifapentine and isoniazid (medicines to prevent tuberculosis). It may help find the right dose for kids who have HIV and are at risk for TB.
Ibadan, Oyo StateAges 4 weeks–11 years - NCT06497465RecruitingPhase 3
HIV study for people starting TB treatment
This trial tests a two-drug HIV treatment (dolutegravir and lamivudine) for people who also have active TB and are taking a standard TB medicine called rifampin. It is designed for those who have not yet started HIV treatment.
Manaus, AmazonasAges 15–99 - NCT02140255RecruitingPhase 1/Phase 2
Intensive early HIV treatment in newborns to aim for remission
This study gives very early, intensive HIV medicine to infants diagnosed with HIV and follows them closely to see if HIV can go into remission (stop being detectable without ongoing treatment). It may help families understand whether treating right after birth can change a child’s long-term HIV outlook.
La Jolla, CaliforniaAges Up to 2 days - NCT07393659RecruitingPhase 3
Continued access to HIV treatment after a parent study
This study lets people who finished an earlier HIV treatment study keep getting the same medicine while a new trial is set up. It helps ensure you don't have a gap in your treatment.
Durban, KwaZulu-NatalAges Any age - NCT06805656RecruitingPhase 2
Trial to reduce HIV reservoirs aiming for treatment-free remission
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
São Paulo, São PauloAges 18–65 - NCT06762054Recruiting
Better management for dolutegravir-resistant HIV
This trial tests better ways to manage HIV when the virus becomes resistant to dolutegravir (DTG), a key medicine. It is for people with high viral load despite being on DTG for at least six months.
KisumuAges 1 year+ - NCT06774872RecruitingPhase 2
Comparing two-drug HIV maintenance treatments
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
Paris, Île-de-France RegionAges 18 years+ - NCT06485154RecruitingPhase 4
Finding the best HIV treatment after PrEP shot failure
This trial is for people who got exposed to HIV despite taking the long-acting PrEP shot (cabotegravir). It tests different pill-based HIV treatment plans to find the best option for them.
Johannesburg, GautengAges 15 years+ - NCT06607588Recruiting
Studying HIV drug resistance in Mozambique
This study looks for HIV drug resistance in people who have been on a specific first-line HIV medication (TLD) for at least 6 months and still have detectable virus. It aims to understand if resistance is developing so that better treatments can be planned.
ChokwéAges 18 years+ - NCT05630638RecruitingPhase 4
Doravirine dose testing during pregnancy for breastfeeding mothers
This study tests how to best dose doravirine for pregnant people with HIV who plan to breastfeed after delivery. The goal is to keep the HIV treatment working safely for both pregnancy and breastfeeding.
Cape TownAges 18 years+ - NCT05069688RecruitingPhase 1
Testing dolutegravir dosing in HIV and TB children
This study looks at the right way to dose dolutegravir (an HIV medicine) in young children who also have active tuberculosis (TB). Doctors will measure how the medicine moves through the body, especially when standard vs higher-dose rifampicin is used.
Ibadan, Oyo StateAges 4 weeks–5 years - NCT07202546RecruitingPhase 2
New oral HIV drug trial for people new to treatment
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
Bakersfield, CaliforniaAges 18 years+ - NCT07711223RecruitingPhase 1/Phase 2
New HIV pill compared to standard treatment for untreated adults
This trial compares a new HIV medication (ACC017) to an existing one (dolutegravir) in adults who have HIV but have never taken HIV drugs before. The goal is to see if the new pill works as well and is safe.
BeijingAges 18 years+ - NCT03884673Recruiting
Simpler two-drug HIV treatment with dolutegravir and lamivudine
This trial studies whether taking dolutegravir plus lamivudine (a simpler two-drug regimen) can work as well as a standard three-drug HIV regimen for people who have reasons they can’t stay on the usual medicines. You may be offered free treatment if you meet the safety checks and can attend follow-up visits.
Guangzhou, GuangdongAges 18 years+ - NCT06250504RecruitingPhase 3
HIV prevention study for young adults
This study tests a long-acting HIV prevention shot (Cabotegravir) or a vaginal ring (DapiRing) along with sexual health services for young people. It aims to find the best way to prevent HIV and support overall health.
Somkele, KwaZulu-NatalAges 15–30 - NCT07336797RecruitingPhase 2
Empagliflozin for weight and metabolism in HIV
This trial tests if empagliflozin, a diabetes medicine, can improve weight and metabolism in people with HIV who take dolutegravir and have a high body mass index (BMI). It may help reduce weight gain linked to HIV treatment.
CairoAges 18–65
What Dolutegravir is being studied for
Conditions with recruiting Dolutegravir studies.
Common questions
- Are there clinical trials studying Dolutegravir?
- Yes. Clin2 currently lists 22 recruiting studies that include Dolutegravir, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Dolutegravir trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Dolutegravir an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Dolutegravir or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.